


Supplementary Figure 5

Principle Component Analysis in different subtypes compared to match HV.

a-d. Serine Threonine kinase (STK)


a

HR-positive HER2 negative pts Vs HVs




b

HR-positive HER2 positive pts Vs HVs




c

Triple negative pts Vs HVs




d

HR-negative HER2 positive pts Vs HVs




e-h. Phosphotyrosine kinase (PTK)


e
HR-positive HER2 negative patients Vs HVs




f
HR-positive HER2 positive patients Vs HVs



g
Triple negative patients Vs HVs



h
HR-negative HER2 positive patients Vs HVs



Principle Component Analysis in different subtypes compared to match HV.

a-d: Principal Component Analysis (PCA) of the different subtypes of breast cancer compared to HVs for the STK family of kinases.

a. HR-positive HER2 negative breast cancer (represented by ER pos) and HVs (represented by C Healthy); b: patients with HR-positive HER2 positive breast cancer (represented by ER pos HER2 pos) and HVs (represented by C Healthy); c: patients with HR-negative HER2 positive breast cancer (represented by ER neg HER2 pos) and HVs (represented by C Healthy); d: patients with Triple negative breast cancer (represented by Triple neg) and HVs (represented by C Healthy).

e-h Principal Component Analysis (PCA) of the different subtypes of breast cancer compared to HVs for the PTK family of kinases.

e: patients with HR-positive HER2 negative breast cancer (represented by ER pos) and HVs (represented by C Healthy); f: patients with HR-positive HER2 positive breast cancer (represented by ER pos HER2 pos) and HVs (represented by C Healthy); g: patients with HR-negative HER2 positive breast cancer (represented by ER neg HER2 pos) and HVs (represented by C Healthy); h: patients with Triple negative breast cancer (represented by Triple neg) and HVs (represented by C Healthy).